GlaxoSmithKline (GSK) and Gilead Sciences, Inc announced a licensing agreement to commercialise Viread (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia.
The details can be read here.
No comments:
Post a Comment